Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METADATE ER vs ADDERALL 30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methylphenidate is a central nervous system stimulant that inhibits the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their concentrations in the synaptic cleft. It also acts as a weak agonist at serotonin receptors.
Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy (off-label)
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
Initial: 10-20 mg orally once daily in the morning. May increase by 10-20 mg at weekly intervals. Maximum: 60 mg/day.
Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day
Terminal elimination half-life: 3-6 hours (mean 4.5 hours) for methylphenidate; clinical context: requires multiple daily dosing or extended-release formulation.
Terminal elimination half-life: d-amphetamine 10-13 hours, l-amphetamine 13-15 hours; in adults (children: 6-8 hours). The longer half-life allows for once-daily dosing.
Primarily hepatic via carboxylesterase CES1A1 to inactive metabolite ritalinic acid. Minor pathways include oxidative metabolism via CYP2D6. The drug undergoes extensive first-pass metabolism.
Primarily hepatic via CYP2D6, with minor contributions from CYP1A2, CYP2B6, and CYP3A4.
Renal (80% as metabolites, <1% unchanged); fecal (10-20%) via biliary elimination.
Approximately 30-40% of a dose is excreted unchanged in urine; the remainder is metabolized primarily by oxidative deamination and aromatic hydroxylation. Biliary/fecal elimination accounts for less than 5%.
10-33% (primarily albumin).
Approximately 20-25% bound to plasma proteins, mainly albumin and alpha-1-acid glycoprotein.
Vd: 2-4 L/kg; indicates extensive tissue distribution and penetration into the central nervous system.
Vd: 3-4 L/kg (approximately 210-280 L for a 70 kg adult). This indicates extensive tissue distribution and penetration into the central nervous system.
Oral: 30% (due to first-pass metabolism); Metadate ER: similar to immediate-release with extended dissolution profile.
Oral immediate-release: approximately 75-100%; oral extended-release: approximately 94% relative to immediate-release. Food does not significantly affect absorption but may delay peak concentration.
No specific guidelines; use with caution in severe renal impairment (e GFR <30 m L/min/1.73m²) and consider dose reduction based on tolerability.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%. Child-Pugh Class C: Not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use
Age ≥6 years: Initial 10-20 mg orally once daily; increase by 10 mg weekly. Maximum: 60 mg/day or 2 mg/kg/day, whichever is less.
Children 3-5 years: initial 2.5 mg orally once daily; increase by 2.5 mg weekly; usual range 2.5-20 mg/day. Children ≥6 years: initial 5 mg once or twice daily; increase by 5 mg weekly; usual range 5-40 mg/day in divided doses
Initiate at lower doses (e.g., 10 mg once daily) with cautious titration due to increased sensitivity and higher risk of adverse effects such as hypertension, agitation, and insomnia.
Initiate at 2.5 mg orally once or twice daily; titrate slowly; monitor for cardiovascular effects, insomnia, and weight loss
METADATE ER has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events. Physicians should assess the risk of abuse before prescribing and monitor for signs of abuse during therapy.
Amphetamines have a high potential for abuse and dependence. Misuse may cause sudden death or serious cardiovascular events.
Serious cardiovascular events including sudden death in patients with structural cardiac abnormalities or other serious heart problems,Increased blood pressure and heart rate,Psychiatric adverse reactions including exacerbation of pre-existing psychosis, mania, or aggression,Seizures in patients with history of seizure disorders,Long-term suppression of growth in children,Potential for peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome when used with serotonergic drugs,Hematologic effects such as leukopenia and thrombocytopenia
Risk of serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities,Increased blood pressure and heart rate,Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggressive behavior,Serotonin syndrome risk when co-administered with serotonergic drugs,Long-term suppression of growth in children,Seizure risk in patients with history of seizures,Peripheral vasculopathy including Raynaud's phenomenon,Visual disturbances due to mydriasis
Hypersensitivity to methylphenidate or any component of the formulation,Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy,Glaucoma,Hyperthyroidism or thyrotoxicosis,Tics or family history of Tourette's syndrome,Severe hypertension or other cardiovascular conditions,History of drug abuse or dependence
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Known hypersensitivity to amphetamines,Agitated states,History of drug abuse,During or within 14 days of MAO inhibitor use,Glaucoma
Take with or without food. High-fat meals may delay the rate of absorption but not the extent. Avoid excessive caffeine intake as it may increase side effects like nervousness and palpitations. Alcohol should be avoided due to risk of altered release and increased adverse effects.
Avoid high-fat meals as they delay absorption; avoid acidic foods (e.g., citrus) and vitamin C supplements within 1 hour of dosing as they decrease absorption; limit caffeine and other stimulants to avoid additive cardiovascular effects.
First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Increased risk of premature delivery, low birth weight, and neonatal withdrawal symptoms (including irritability, dysphoria, and feeding difficulties).
Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased risk of premature delivery, low birth weight, and neonatal withdrawal symptoms (e.g., dysphoria, agitation, lassitude). Chronic use may lead to neonatal toxicity.
Methylphenidate is excreted into breast milk in low concentrations (M/P ratio approximately 2.5). Short-term use is considered compatible with breastfeeding; however, observe infant for agitation, insomnia, and reduced weight gain. Avoid long-acting formulations due to higher milk concentrations.
Excreted in breast milk. M/P ratio unknown. Potential for stimulant effects in infant (e.g., irritability, poor feeding, insomnia). Caution advised; consider alternative feeding methods.
Increased clearance and volume of distribution during pregnancy may require dose adjustments. Plasma levels decrease by approximately 50% in the third trimester; consider increasing dose or switching to immediate-release formulation with more frequent dosing. Postpartum, monitor for toxicity as clearance returns to prepregnancy levels.
No established dosing guidelines. Due to increased plasma volume and clearance, dose may need titration to clinical effect, but avoid supratherapeutic doses. Use lowest effective dose.
METADATE ER is an extended-release formulation of methylphenidate. Avoid crushing or chewing capsules to prevent rapid release and potential toxicity. Monitor for blood pressure and heart rate changes, especially in patients with pre-existing cardiovascular conditions. Use with caution in patients with a history of seizures or drug dependence. Discontinue if signs of psychosis or severe depression occur.
For ADHD: start low, go slow; monitor weight and height in children; avoid late doses to prevent insomnia; check for abuse/diversion; screen for bipolar disorder and hypertension; consider urine drug screen before prescribing; avoid MAOIs within 14 days; use with caution in seizure disorders and glaucoma.
Take exactly as prescribed; do not crush or chew capsules.,Swallow whole with or without food, usually in the morning.,Report any chest pain, shortness of breath, or fainting immediately.,Avoid alcohol while taking this medication.,Store at room temperature away from moisture and heat.,Do not suddenly stop taking without consulting your doctor.,May impair ability to drive or operate machinery until effects are known.
Take exactly as prescribed; do not crush or chew capsules.,Take the first dose upon waking; avoid afternoon/evening doses.,May cause insomnia, loss of appetite, or nervousness.,Do not drink alcohol while taking this medication.,Report chest pain, palpitations, shortness of breath, or mood changes.,Store securely; do not share medication with others.,Regular blood pressure and heart rate monitoring is necessary.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METADATE ER vs ADDERALL 30, answered by our medical review team.
METADATE ER is a CNS Stimulant that works by Methylphenidate is a central nervous system stimulant that inhibits the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their concentrations in the synaptic cleft. It also acts as a weak agonist at serotonin receptors.. ADDERALL 30 is a CNS Stimulant that works by Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METADATE ER and ADDERALL 30 depend on the specific clinical indication. These are both CNS Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METADATE ER is: Initial: 10-20 mg orally once daily in the morning. May increase by 10-20 mg at weekly intervals. Maximum: 60 mg/day.. The standard adult dose of ADDERALL 30 is: Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METADATE ER and ADDERALL 30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METADATE ER is classified as Category C. First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Increased risk of premature delive. ADDERALL 30 is classified as Category C. Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased r. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.